Frederick, Maryland-based Cartesian Therapeutics (Nasdaq: RNAC) has announced a non-dilutive credit facility of up to USD 150 million with K2 HealthVentures LLC. The move is designed to help fund pre-commercial launch preparations for its lead mRNA CAR-T asset and extend its cash runway through 2028, ahead of three near-term clinical data readouts.
The facility is structured as a series of term loans. An initial USD 50 million tranche was funded at signing. A second tranche of USD 25 million is drawable between January 1 and December 1, 2027, subject to the company meeting specified clinical and financing milestones. A third tranche of USD 25 million is available between January 1 and June 1, 2028, contingent on approval and sales milestones. An additional optional tranche of USD 50 million may be drawn at Cartesian's election, subject to K2 HealthVentures' discretion. No syndicate members or co-lenders were named.
Company overview and pipeline
Cartesian Therapeutics is a late clinical-stage biotechnology company focused on mRNA-based cell therapy for autoimmune diseases. Its lead asset, Descartes-08, is an autologous BCMA-directed mRNA CAR-T therapy distinguished by its design for outpatient administration without preconditioning lymphodepleting chemotherapy, which the company states removes the genomic integration risk associated with conventional DNA-based CAR-T constructs. Descartes-08 holds Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the US FDA for myasthenia gravis, and Rare Pediatric Disease Designation for juvenile dermatomyositis.
The most advanced program is the Phase III AURORA trial (NCT06799247) in acetylcholine receptor autoantibody-positive generalized myasthenia gravis. The randomized, double-blind, placebo-controlled study enrolls approximately 100 patients receiving six once-weekly outpatient infusions of Descartes-08 or placebo in a 1:1 ratio. The primary endpoint measures the proportion of patients achieving a three-point or greater improvement in the MG Activities of Daily Living score at month four. Topline data are expected in Q1 2027, with a biologics license application filing planned for mid-2027. Supporting this program, a peer-reviewed Phase 2b randomized controlled trial published in Nature Medicine in 2026 reported an average 4.8-point reduction in MG-ADL at month 12 following a single course of therapy; in biologic-naive patients, the average reduction reached 7.1 points, with 57% of that subgroup maintaining minimum symptom expression at month 12.